<DOC>
	<DOC>NCT00269087</DOC>
	<brief_summary>This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.</brief_summary>
	<brief_title>GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<mesh_term>Bronchitis, Chronic</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Diagnosis of COPD. Exclusion criteria: Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other than COPD. Other inclusion and exclusion criteria will be evaluated at the first study visit.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>COPD</keyword>
	<keyword>Emphysema</keyword>
</DOC>